Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hunting sees profit jump by half, opens door to acquisitions

(Sharecast News) - Hunting saw its full-year profits jump by half, saw its free cash flow swing sharply back into the black and opened the door to potential acquisitions. "I would like to thank our workforce and senior leadership team for delivering a further year of revenue, EBITDA and adjusted earnings growth, despite the volatile energy markets reported in 2024," chief executive officer Jim Johnson told investors.

"Hunting continues to deliver on its 2030 strategic objectives, supported by strong offshore and international markets. Our cash generation in the year has also been outstanding, and we now look to deploy this to acquisitive growth and investments to enhance productivity and stronger dividend distributions."

The equipment manufacturer for the global oil and gas industry reported a 12.8% jump in revenues to reach approximately $1.05bn.

That resulted in a 51.2% jump in its adjusted profit before tax to reach $75.6m and a similar improvement in earnings per share to US 31.4 cents.

Free cash flow meanwhile swung from -$0.8m in 2023 to $104.7m and its return on capital employed rose by three percentage points to 9%.

Total cash and bank deposits at period end stood at $104.7m, having finished the previous year at -$800,000.

The final dividend proposed by the company's board was increased by US 1 cent to 6 cents.

As of 1215 BST, shares of Hunting had fallen by 8.79% to 280.0p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.